Fig. 3

FAM73b regulates anti-tumor responses in myeloid cells. a, b Tumor growth curve and survival curve of T-cell-specific KO mice (n = 8) injected with 2 × 10⁵ B16 melanoma cells. c WT and T-cell-specific KO naive CD4⁺ T cells (CD44^loCD62L^hi) were stimulated for 4 days with plate-bound anti-CD3 and anti-CD28 antibodies under subpopulation conditions. The frequency of T-cell differentiation was analyzed by flow cytometry based on intracellular staining of cytokines. d Heat map showing basal differentially expressed genes in naive T cells from WT and T-cell-specific KO mice. e, f Tumor growth curve (e) and survival curve (f) of myeloid cell-specific KO (n = 8) mice injected with 2 × 10⁵ B16 melanoma cells. g, h Flow cytometric analysis of immune cells (CD45⁺) that infiltrated day 15 tumors and the frequency of CD4⁺ T cells, CD8⁺ T cells, macrophages (CD11b⁺F4/80⁺), myeloid derived suppressor cells (MDSCs) (CD11b⁺Gr-1⁺) (g) and Treg cells (CD4⁺Foxp3⁺) (h). Summary of flow cytometry data based on multiple animals, showing the frequency of the indicated cell populations within total tumor cells (right panel). i ICS and flow cytometric analysis of IFNγ⁺ in CD8⁺ T tumor or dLN cells, presented as a representative plot (left panel) and a summary graph (right panel). j qRT-PCR analysis of the indicated genes in TAMs isolated from tumors in WT or myeloid cell-specific KO mice. All qRT-PCR data are presented as fold-induction relative to the Actb mRNA level. The data are the mean ± SEM value of multiple animals (each circle or square represents a mouse) and representative of three independent experiments. Two-tailed unpaired t-tests were performed. *P < 0.05; **P < 0.01